Primary liver cancer, malignant (ICD10 C22): combined sexes

Five-year relative survival by diagnosis year and age at diagnosis

	One-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	15.9%	24.7%	31.7%	29.2%
(unstandardized)	(11.3-21.1%)	(20.5-29.1%)	(27.9-35.5%)	(25.2-33.3%)

all 15-99	15.7%	25.6%	33.6%	31.8%	20.3%	30.0%
(age-standardized)#	(6.8-27.8%)	(16.5-35.0%)	(25.1-41.9%)	(21.7-41.8%)	(16.0-25.7%)	(29.1-30.9%)

15-44	41.2%	58.0%	50.1%	44.9%
	(18.6-62.7%)	(33.2-76.3%)	(28.2-68.5%)	(20.7-66.5%)

45-54	15.9%	40.2%	48.2%	49.3%
	(3.9-35.0%)	(25.9-54%)	(34.1-60.9%)	(31.2-65.0%)

55-64	17.4%	23.3%	39.7%	36.8%
	(7.1-31.5%)	(15.5-31.9%)	(31.3-48.0%)	(26.4-47.1%)

65-74	15.3%	15.5%	36.5%	37.4%
	(8.6-23.7%)	(9.59-22.6%)	(29.5-43.5%)	(28.9-45.8%)

75-99	8.6%	23.8%	15.9%	11.8%
	(3.2-17.5%)	(16.4-32.1%)	(11.2-21.3%)	(7.1-17.9%)

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	4.3%	10.8%	12.9%	12.8%
(unstandardized)	(2.0-8.0%)	(7.7-14.4%)	(9.4-17.0%)	(9.3-16.8%)

all 15-99	-	11.0%	13.3%	13.4%	6.4%	9.1%
(age-standardized)#		(5.1-19.3%)	(6.6-22.6%)	(6.3-23.4%)	(3.8-10.7%)	(8.4-9.7%)

15-44	17.7%	37.0%	26.7%	28.2%
	(4.4-38.5%)	(16.6-57.7%)	(9.2-48.0%)	(8.7-51.9%)

45-54	-	11.2%	26.0%	22.7%
		(4.1-22.4%)	(12.4-42.0%)	(10.2-38.1%)

55-64	-	12.6%	16.7%	15.1%
		(6.9-20.2%)	(9.4-26.0%)	(8.1-24.1%)

65-74	5.1%	2.9%	13.1%	14.9%
	(1.7-11.6%)	(0.8-7.5%)	(7.7-20.0%)	(8.3-23.3%)

75-99	1.9%	11.4%	2.5%	3.0%
	(0.2-9.0%)	(5.6-19.9%)	(0.5-7.9%)	(0.6-9.4%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,

supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival).

In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

## For comparison, the age-standardized average survival is quoted for countries (including Ireland) that participated in the EUROCARE-4 study:

Sant M. et al. 2009. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.

- = insufficient data for some age-groups